Comment on the article of E.A. Lebedeva et al. “Basic therapy of traumatic brain injury using catecholamine agonist”
ISSN (print) 1726-9806     ISSN (online) 1818-474X
#2018-1
PDF_2018-1_83 (Russian)

How to Cite

1.
Belkin A.A. Comment on the article of E.A. Lebedeva et al. “Basic therapy of traumatic brain injury using catecholamine agonist.” Annals of Critical Care. 2018;(1):83. Accessed September 13, 2024. https://intensive-care.ru/index.php/acc/article/view/126

Statistic

Abstract Views: 58
PDF_2018-1_83 (Russian) Downloads: 43
Statistic from 01.07.2024

Language

English Русский

Social Networks

Abstract

Comment on the article of E.A. Lebedeva et al. “Basic therapy of traumatic brain injury using catecholamine agonist”
PDF_2018-1_83 (Russian)

References

  1. Samson A.J., Robertson G., Zagnoni M., Connolly C.N. Neuronal networks provide rapid neuroprotection against spreading toxicity. Sci. Rep. 2016; 6: 33746. doi: 10.1038/srep33746.
  2. Giacino J.T., Whyte J., Bagiella E., et al. Placebo-Controlled Trial of Amantadine for Severe Traumatic Brain Injury. N. Engl. J. Med. 2012; 366(9): 819–826. doi: 10.1056/NEJMoa1102609.
  3. Kalmar K., Childs N., et al. Placebo-Controlled Trial of Amantadine for Severe Traumatic Brain Injury. Rehabilitation. 2012; 366(9): 819–826. doi: 10.1056/NEJMoa110260.
  4. Belkin A.A., Shchegolev A.V., Kondrat’ev A.N., Bubnova I.D. Use of amantadine sulfate (PK-MERZ) during emergence from coma: results of a multicenter study. Anesteziol. Reanimatol. 2008; 2: 70–73. PMID: 18540467.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright (c) 2018 ANNALS OF CRITICAL CARE